Identifying patterns of failure and secondary primary malignancies in HPV-related oropharyngeal squamous cell carcinomas

Papers of special note have been highlighted as: • of interest

References

• 1. Ferlay J, Shin H, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893–2917 (2010).
  Medline CASGoogle Scholar
• 2. Masterson L, Moualed D, Liu ZW et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur. J. Cancer 50(15), 2636–2648 (2014).
  MedlineGoogle Scholar
• 3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).
  MedlineGoogle Scholar
• 4. Klussmann JP, Weissenborn SJ, Wieland U et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92(11), 2875–2884 (2001).
  Medline CASGoogle Scholar
• 5. Smith EM, Ritchie JM, Summersgill KF et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Intl. J. Cancer 108(5), 116–133 (2003).
  Google Scholar
• 6. Reed AL, Califan J, Cairns P et al. High frequency of p16 (CDKN2/MTS-1/INK4a) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56(16), 3630–3633 (1996).
  Medline CASGoogle Scholar
• 7. Mellin H, Friesland S, Lowensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int. J. Cancer 89(3), 300–304 (2000).
  Medline CASGoogle Scholar
• 8. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92(9), 709–720 (2000).
  Medline CASGoogle Scholar
• 9. Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 3(1), 78–81 (2009).
  MedlineGoogle Scholar
• 10. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16(3), 1197–1206 (1998).
  Medline CASGoogle Scholar
• 11. Munger K, Baldwin A, Edwards KM et al. Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78(21), 11451–11460 (2004).
  MedlineGoogle Scholar
• 12. Goodman MT, Saraiya M, Thompson TD et al. Human papillomavirus genotype and oropharynx cancer survival in the United States. Eur. J. Cancer 51(18), 2759–2767 (2015).
  MedlineGoogle Scholar
• 13. Preuss SF, Weinell A, Molitor M et al. Nuclear surviving expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br. J. Cancer 98(3), 627–632 (2008).
  Medline CASGoogle Scholar
• 14. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Onc. 48(12), 1191–1201 (2012).
  MedlineGoogle Scholar
• 15. Amin MB, Edge S, Greene F et al. American Joint Committee on Cancer. In: AJCC Cancer Staging Manual (8th Edition). Springer International Publishing, NY, USA (2018).
  Google Scholar
• 16. Marur S, Li S, Cmelak AJ et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx. J. Clin. Onc. 35(5), 490–497 (2017).
  Medline CASGoogle Scholar
• 17. Misiukiewicz K, Gupta V, Miles BA et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients. Oral Onc. 93(1), 170–177 (2019).
  Google Scholar
• 18. Misiukiewicz K, Camille N, Gupta V et al. The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin. Adv. Hematol. Oncol. 12(12), 812–819 (2014).
  MedlineGoogle Scholar
• 19. Muller S, Khuri FR, Kono SA, Beitler JJ, Shin DM, Saba NF. HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol. 6(3), 336–344 (2012).
  MedlineGoogle Scholar
• 20. Trosman SJ, Koyfman SA, Ward MC et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol. Head Neck Surg. 141(5), 457–462 (2015). • Retrospective study which reveals differences in metastatic failure between patients with human papilloma virus (HPV)-positive and -negative primary tumors.
  MedlineGoogle Scholar
• 21. Masroor F, Corpman D, Carpenter DM, Weintraub MR, Cheung KHN, Wang KH. Association of NCCN-recommended posttreatment surveillance with outcomes in patients with HPV-associated oropharyngeal squamous cell carcinoma. JAMA Otolaryngol. Head Neck Surg. 145(10), 903–908 (2019).
  MedlineGoogle Scholar
• 22. Geurts TW, Nederlof PM, van den Brekel WM et al. Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin. Cancer Res. 11(18), 6608–6614 (2005).
  MedlineGoogle Scholar
• 23. Fakhry C, Westra WH, Cmelak A et al. Improved survival of patient with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Int. 100(4), 261–269 (2008).
  Medline CASGoogle Scholar
• 24. Sinha P, Thorstad WT, Nussenbaum B et al. Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. Oral Oncol. 50(1), 45–51 (2014).
  Medline CASGoogle Scholar
• 25. Morris LGT, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J. Clin. Oncol. 29(6), 739–746 (2011). • SEER analysis which shows decreased rate of second primary malignancies in the head, neck and lung in patients with HPV-positive primary tumors.
  MedlineGoogle Scholar
• 26. Xu C, Biron VL, Puttagunta L, Seikaly H. HPV status and second primary tumours in oropharyngeal squamous cell carcinoma. J. Otolaryngol. Head Neck Surg. 439(1), 1–6 (2013).
  Google Scholar
• 27. Adjei BE, Buchanan P, Hinyard L, Osazuwa-Peters N, Schootman M, Piccirillo JF. Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngol. Head Neck Surg. 144(8), 727–737 (2018).
  MedlineGoogle Scholar
• 28. Peck BW, Dahlstrom KR, Gan SJ et al. Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. Head Neck 35(6), 794 (2013).
  MedlineGoogle Scholar
• 29. Lee DH, Roh JL, Baek S et al. Second cancer incidence, risk factor, and specific mortality in head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 149(4), 579–586 (2013).
  MedlineGoogle Scholar
• 30. Diaz DA, Reis IM, Weed DT, Elsayyad N, Samuels M, Abramowitz MC. Head and neck second primary cancer rates in the human papillomavirus era: a population-based analysis. Head Neck 38(Suppl. 1), E873–E883 (2016).
  MedlineGoogle Scholar
• 31. Suk R, Mahale P, Sonawane K et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw. Open 1(1), 1–13 (2018).
  Google Scholar
• 32. Hemminki K, Dong C, Vaittinen P. Second primary cancer after in situ and invasive cervical cancer. Epidemiology 11(4), 457–461 (2000). • Population study in Sweden which reports second primary malignancies in patients with HPV-associated cervical cancer.
  Medline CASGoogle Scholar
• 33. Teng CJ, Huon LK, Hu YW et al. Secondary primary malignancy risk in patients with cervical cancer in Taiwan. Medicine (Baltimore) 94(43), e1803 (2015).
  MedlineGoogle Scholar
• 34. Berfeldt K, Einhorn S, Rosendahl I, Hall P. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study. Acta Oncol. 34(6), 771–777 (1995).
  MedlineGoogle Scholar
• 35. Clifford GM, Franceschi S, Keiser O et al. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: a nested case-control study in the Swiss HIV cohort study. Int. J. Cancer 138(7), 1732–1740 (2016).
  Medline CASGoogle Scholar
• 36. Hu G, Wu P, Cheng P et al. Tumor-infiltrating CD39 Tregs are novel immunosuppressive T cells in human colorectal cancer. J. Oncoimmunol. 6(2), 2 (2017).
  CASGoogle Scholar
• 37. Wittke F, Hoffmann R, Buer J et al. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br. J. Cancer 79(12), 1182–1184 (1999).
  Medline CASGoogle Scholar
• 38. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 349(9049), 398 (1997). • Looks at increased risk of melanoma in the setting of immunosuppression.
  Medline CASGoogle Scholar
• 39. Oguejiofor K, Galletta-Williams H, Dovedi SJ, Roberts DL, Stern PL, West CML. Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV – oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget 8(9), 14416–14427 (2017).
  MedlineGoogle Scholar
• 40. Lechien JR, Seminerio I, Descamps G et al. Impact of HPV infection on the immune system in oropharyngeal and non-oropharyngeal squamous cell carcinoma: a systematic review. Cells 8(9), 1061 (2019).
  CASGoogle Scholar